2017 was a landmark year for the pharmaceutical industries in the US and Europe, with a sharp increase in the number of new molecular entities (NMEs) being approved in both the geographies.
The US Food and Drug Administration (USFDA) approved 46 NMEs in 2017, a strong bounce back from only 22 NMEs approved in 2016.